Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts

Journal of Bone and Mineral Research

Volumn 26, Issue 1, 2011, Pages 182-192

  Danks, Lynett ^a   Workman, Sarita ^b   Webster, David ^b   Horwood, Nicole J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

B CELLS; IMMUNODEFICIENCY; INFLAMMATION

Indexed keywords

ACTIN; BRUTON TYROSINE KINASE; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOSKELETON; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MUTATION; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; X LINKED AGAMMAGLOBULINEMIA;

ACID PHOSPHATASE; ACTINS; ADULT; AGAMMAGLOBULINEMIA; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; CELLS, CULTURED; CYTOKINES; DENTIN; GENETIC DISEASES, X-LINKED; HUMANS; INFLAMMATION MEDIATORS; ISOENZYMES; MIDDLE AGED; OSTEOCLASTS; PROTEIN-TYROSINE KINASES;

EID: 78650934360     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.210     Document Type: Article

References (42)

1. Horwood NJ, Mahon T, McDaid JP, et al. Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor α production. J Exp Med. 2003; 197: 1603-1611.
2. Mangla A, Khare A, Vineeth V, et al. Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses. Blood. 2004; 104: 1191-1197.
3. Horwood NJ, Page TH, McDaid JP, et al. Bruton's tyrosine kinase is required for TLR2- and TLR4-induced TNF, but not IL-6, production. J Immunol. 2006; 176: 3635-3641.
4. Melcher M, Unger B, Schmidt U, Rajantie IA, Alitalo K, Ellmeier W., Essential roles for the Tec family kinases Tec and Btk in M-CSF receptor signaling pathways that regulate macrophage survival. J Immunol. 2008; 180: 8048-8056.
5. Jongstra-Bilen J, Puig Cano A, Hasija M, Xiao H, Smith CI, Cybulsky MI., Dual functions of Bruton's tyrosine kinase and Tec kinase during FcÎ receptor-induced signaling and phagocytosis. J Immunol. 2008; 181: 288-298.
6. Shinohara M, Koga T, Okamoto K, et al. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell. 2008; 132: 794-806.
7. Takayanagi H., The role of NFAT in osteoclast formation. Ann N Y Acad Sci. 2007; 1116: 227-237.
8. Lee SH, Kim T, Jeong D, Kim N, Choi Y., The Tec Family Tyrosine Kinase Btk Regulates RANKL-induced Osteoclast Maturation. J Biol Chem. 2008; 283: 11526-11534.
9. Yao L, Janmey P, Frigeri LG, et al. Pleckstrin homology domains interact with filamentous actin. J Biol Chem. 1999; 274: 19752-19761.
10. Mukhopadhyay S, Ramars AS, Dash D., Bruton's tyrosine kinase associates with the actin-based cytoskeleton in activated platelets. J Cell Biochem. 2001; 81: 659-665. (Pubitemid 32417090)
11. Bunnell SC, Henry PA, Kolluri R, Kirchhausen T, Rickles RJ, Berg LJ., Identification of Itk/Tsk Src homology 3 domain ligands. J Biol Chem. 1996; 271: 25646-25656.
12. Sharma S, Orlowski G, Song W., Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells. J Immunol. 2009; 182: 329-339.
13. Symons M, Derry JM, Karlak B, et al. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell. 1996; 84: 723-734.
14. Sideras P, Smith CI., Molecular and cellular aspects of X-linked agammaglobulinemia. Adv Immunol. 1995; 59: 135-223.
15. Valiaho J, Smith CI, Vihinen M., BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat. 2006; 27: 1209-1217.
16. Smith CI, Backesjo CM, Berglof A, et al. X-linked agammaglobulinemia: lack of mature B lineage cells caused by mutations in the Btk kinase. Springer Semin Immunopathol. 1998; 19: 369-381.
17. Chun JK, Lee TJ, Song JW, Linton JA, Kim DS., Analysis of clinical presentations of bruton disease: a review of 20 years of accumulated data from pediatric patients at severance hospital. Yonsei Med J. 2008; 49: 28-36.
18. Feldmann M, Maini SR., Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 2008; 223: 7-19.
19. Danks L, Sabokbar A, Gundle R, Athanasou NA., Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann Rheum Dis. 2002; 61: 916-921.
20. Njeh CF, Genant HK., Bone loss. Quantitative imaging techniques for assessing bone mass in rheumatoid arthritis. Arthritis Res. 2000; 2: 446-450.
21. Palmer CD, Mutch BE, Workman S, McDaid JP, Horwood NJ, Foxwell BM., Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFkapp}B activity. Blood. 2008; 111: 1781-1788.
22. Bruzzaniti A, Neff L, Sanjay A, Horne WC, De Camilli P, Baron R., Dynamin forms a Src kinase-sensitive complex with Cbl and regulates podosomes and osteoclast activity. Mol Biol Cell. 2005; 16: 3301-3313.
23. Rawlings DJ, Scharenberg AM, Park H, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science. 1996; 271: 822-825.
24. Biswas RS, Baker D, Hruska KA, Chellaiah MA., Polyphosphoinositides- dependent regulation of the osteoclast actin cytoskeleton and bone resorption. BMC Cell Biol. 2004; 5: 19.
25. Guinamard R, Aspenstrom P, Fougereau M, Chavrier P, Guillemot JC., Tyrosine phosphorylation of the Wiskott-Aldrich syndrome protein by Lyn and Btk is regulated by CDC42. FEBS Lett. 1998; 434: 431-446.
26. Amoras AL, Kanegane H, Miyawaki T, Vilela MM., Defective Fc-, CR1- and CR3-mediated monocyte phagocytosis and chemotaxis in common variable immunodeficiency and X-linked agammaglobulinemia patients. J Investig Allergol Clin Immunol. 2003; 13: 181-188.
27. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y., IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004; 15: 49-60.
28. Schett G., Review: Immune cells and mediators of inflammatory arthritis. Autoimmunity. 2008; 41: 224-229.
29. Algan SM, Purdon M, Horowitz SM., Role of tumor necrosis factor alpha in particulate-induced bone resorption. J Orthop Res. 1996; 14: 30-35.
30. Graves DT., The potential role of chemokines and inflammatory cytokines in periodontal disease progression. Clin Infect Dis. 1999; 28: 482-490.
31. Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun. 2000; 275: 768-775.
32. Brandstrom H, Bjorkman T, Ljunggren O., Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun. 2001; 280: 831-835.
33. Horwood NJ, Elliott J, Martin TJ, Gillespie MT., Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology. 1998; 139: 4743-4746.
34. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A., Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem. 2000; 275: 4858-4864.
35. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000; 191: 275-286.
36. Palmqvist P, Persson E, Conaway HH, Lerner UH., IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol. 2002; 169: 3353-3362.
37. Paganelli M, Albanese C, Borrelli O, et al. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 416-423.
38. Axmann R, Bohm C, Kronke G, Zwerina J, Smolen J, Schett G., Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum. 2009; 60: 2747-2756.
39. Pfeilschifter J, Chenu C, Bird A, Mundy GR, Roodman GD., Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J Bone Miner Res. 1989; 4: 113-118.
40. Kitazawa R, Kimble RB, Vannice JL, Kung VT, Pacifici R., Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest. 1994; 94: 2397-2406.
41. Nakamura I, Kadono Y, Takayanagi H, et al. IL-1 regulates cytoskeletal organization in osteoclasts via TNF receptor-associated factor 6/c-Src complex. J Immunol. 2002; 168: 5103-5109.
42. Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ., Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J Bone Miner Res. 2000; 15: 1459-1466.